Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Huilai Zhang et al.|The Lancet Oncology|2023Cited by 61
<i>KMT2D</i> mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axisQing-Xiao Liu, Weili Zhao|International Journal of Biological Sciences|2024Cited by 16
Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up ResultsXinxin Cao, Daobin Zhou, Jie Jin et al.|Blood|2023Cited by 4